TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Novartis has secured approval from the Egyptian Drug Authority to use Kisqali for treating early-stage breast cancer. This marks a new indication for the drug in Egypt, potentially impacting local cancer treatment options.
Novartis has obtained approval from the Egyptian Drug Authority (EDA) to expand the use of its breast cancer medication, Kisqali, for the treatment of early-stage breast cancer, the company announced on March 2024. This marks a significant regulatory milestone for the drug in Egypt, potentially broadening treatment options for patients with this form of cancer.
The approval follows a review process by the EDA, which evaluated data supporting Kisqali’s safety and efficacy for early-stage breast cancer. Kisqali, known generically as ribociclib, is already approved in several countries for advanced breast cancer, often in combination with hormone therapy. The Egyptian approval is specifically for use in early-stage cases, where it is intended to be part of a comprehensive treatment plan.
According to Novartis, this approval is based on clinical trial data demonstrating the drug’s ability to improve disease-free survival in patients with early-stage hormone receptor-positive, HER2-negative breast cancer. The company highlighted that this new indication aligns with its strategy to expand access to innovative therapies in emerging markets like Egypt.
Potential Impact on Local Breast Cancer Treatment in Egypt
This approval could significantly influence breast cancer management in Egypt by providing a new, targeted treatment option for early-stage patients. It may lead to earlier intervention, potentially improving long-term outcomes and reducing recurrence rates. The move also signals increased regulatory acceptance of advanced cancer therapies in Egypt, which could encourage further approvals and investments in oncology treatments.
For patients, this means access to a therapy that has demonstrated efficacy in clinical trials, possibly improving quality of life and survival prospects. Healthcare providers may need to update treatment protocols to include Kisqali where appropriate, and insurance coverage policies could also evolve to support its use.
Kisqali (ribociclib) breast cancer medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background on Kisqali and Its Global Use in Breast Cancer
Kisqali (ribociclib) is a CDK4/6 inhibitor developed by Novartis, approved in multiple countries for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is typically used in combination with hormone therapies such as letrozole or fulvestrant.
In recent years, clinical trials have shown that Kisqali can significantly extend progression-free survival in early-stage breast cancer when combined with hormone therapy, leading to its approval for this indication in several regions. The drug’s approval in Egypt marks a notable expansion of its geographic reach, reflecting a broader trend toward adopting targeted therapies in emerging markets.
Interest in Kisqali has surged in recent months, driven by ongoing research and expanding indications, although specific details about the Egyptian approval process have not been publicly disclosed beyond the announcement.
“The EDA’s approval of Kisqali for early-stage breast cancer reflects our rigorous review process and confidence in the drug’s safety and efficacy data.”
— Egyptian Drug Authority official
CDK4/6 inhibitors for breast cancer
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unconfirmed Details About Approval Scope and Market Impact
It is not yet clear whether Kisqali’s approval in Egypt includes specific age groups, dosing protocols, or whether it will be covered by national health insurance. Details about the approval process, such as the review timeline or the clinical trial data submitted, remain undisclosed. Additionally, the extent to which this will influence regional treatment guidelines or prompt further approvals in neighboring countries is still uncertain.
early-stage breast cancer treatment drugs
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for Kisqali’s Adoption and Market Penetration in Egypt
Healthcare providers in Egypt will likely begin integrating Kisqali into treatment protocols for early-stage breast cancer, pending official guidelines. Novartis may collaborate with local health authorities and hospitals to facilitate access and education. Meanwhile, further regulatory reviews or approvals in other Middle Eastern and North African countries could follow, depending on regional demand and clinical data sharing.
Monitoring of patient outcomes and insurance coverage policies will be critical in assessing the real-world impact of this new indication.
hormone receptor-positive breast cancer therapy
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is Kisqali used for?
Kisqali (ribociclib) is a targeted therapy used primarily for hormone receptor-positive, HER2-negative breast cancer, typically in advanced stages. The recent approval in Egypt extends its use to early-stage treatment.
Does this approval mean Kisqali is now available in Egypt?
Yes, the approval from the Egyptian Drug Authority indicates Kisqali can now be prescribed for early-stage breast cancer patients in Egypt, subject to local healthcare policies and physician approval.
Will this approval affect breast cancer treatment options in Egypt?
It could expand treatment options by providing a new targeted therapy, potentially improving outcomes for early-stage patients. The actual impact depends on availability, cost, and integration into clinical practice.
Are there any known side effects or risks associated with Kisqali?
As with other CDK4/6 inhibitors, Kisqali’s side effects may include neutropenia, nausea, fatigue, and liver enzyme elevations. Patients should be monitored closely, and treatment should be guided by healthcare professionals.
When will Kisqali be available for patients in Egypt?
The exact timeline for distribution and prescription availability has not been publicly announced; it may depend on local supply chains and healthcare provider readiness.
Source: local
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
